International randomized trial on the effect of revascularization or optimal medical therapy of chronic total coronary occlusions with myocardial ischemia - ISCHEMIA-CTO trial – rationale and design - 10/02/23
, Salma Karim, MD 2, Ashkan Eftekhari, MD PhD 3, Javier Escaned, MD PhD 4, Dan Ioanes, MD 1, Simon Walsh, MD 5, James Spratt, MD DMSc 6, Karsten Veien, MD PhD 7, Lisette Okkels Jensen, MD PhD DMSci 7, Hans-Henrik Tilsted, MD PhD 8, Christian Juhl Terkelsen, MD PhD 2, Ole Havndrup, MD PhD 9, Niels Thue Olsen, MD PhD 10, Olli A. Kajander, MD PhD 11, Benjamin Faurie, MD 12, Peep Lanematt, MD PhD 13, Lars Jakobsen, MD PhD 2, Evald Høj Christiansen, MD PhD 2Riassunto |
Background |
Chronic total occlusions (CTO) are frequent among patients with coronary artery disease. Revascularization with percutaneous coronary intervention (PCI) is safe and feasible in experienced hands. However, randomized data are needed to demonstrate symptomatic as well as prognostic effect of CTO-PCI compared to optimal medical therapy alone.
Methods |
This trial aims to evaluate the effect of CTO PCI in patients with a CTO lesion and target vessel diameter ≥ 2.5 mm, and myocardial ischemia in the relevant territory. First, all patients are subjected to optimal medical therapy (OMT) for at least for 3 months and non-CTO lesions are managed according to guidelines. Subsequently, prior to randomization myocardial ischemia and quality of life (Seattle Questionnaire (SAQ)) is assessed. Patients are divided into two cohorts based on their SAQ score and randomized to either OMT alone or OMT and CTO-PCI. Cohort A is defined as Low- or asymptomatic patients with a quality-of-life score > 60 and/or CCS class < 2, and more than 10 % ischemia in the left ventricle (LV). Cohort B is symptomatic patients with a quality-of-life score < 60 or CCS class angina > 1 and at least ischemia in 5% of the LV. The primary end-point in cohort A is a composite of major adverse cardiac and cerebral events, hospitalization for heart failure and malignant ventricular arrhythmias. The primary endpoint in cohort B is difference in quality of life 6 months after randomization.
Implications |
This trial is designed to investigate if CTO-PCI improves QoL and MACCE. Both positive and negative outcome of the trial will affect future guidelines and recommendations on how to treat patients with CTO.
Il testo completo di questo articolo è disponibile in PDF.Mappa
Vol 257
P. 41-50 - marzo 2023 Ritorno al numero
Articolo precedente
- Rationale and design of BROKEN-SWEDEHEART: a registry-based, randomized, parallel, open-label multicenter trial to test pharmacological treatments for broken heart (takotsubo) syndrome
- Elmir Omerovic, Stefan James, David Erlinge, Henrik Hagström, Dimitrios Venetsanos, Loghman Henareh, Christina Ekenbäck, Joakim Alfredsson, Kristina Hambreus, Björn Redfors
- The rationale, design, and methods of a trial to evaluate the efficacy and safety of oxygen therapy in patients with intermediate-risk acute pulmonary embolism
- Diego Durán, Deisy Barrios, Jorge Moisés, Ana Retegui, Carmen Rodríguez, José L. Lobo, Raquel López-Reyes, Leyre Chasco, Luis Jara-Palomares, Manuel Monreal, Behnood Bikdeli, David Jiménez
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?